Mulfinya (Fingolimod)

Fingolimod, the active ingredient in Mulfinya, is a sphingosine 1‑phosphate receptor modulator presented as an oral tablet for oral use. It treats relapsing‑remitting multiple sclerosis in adult patients.

GNH USA supplies Mulfinya as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mulfinya (fingolimod) is indicated as a disease‑modifying therapy within the multiple sclerosis treatment pathway.

- Relapsing‑remitting multiple sclerosis: reduces the frequency of clinical relapses and slows disability progression. - Active disease in adults: decreases new inflammatory lesions detected on MRI. - High lesion activity: limits accumulation of new brain lesions over time.

Fingolimod may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Nasopharyngitis: upper respiratory tract infection symptoms. - Diarrhea: loose stools, usually transient. - Elevated liver enzymes: mild transaminase increase. - Fatigue: persistent tiredness. - Cough: dry or productive.

Serious or Rare Side Effects: - Infections: opportunistic or severe bacterial infections. - Cardiac arrhythmia: bradycardia or conduction delays. - Macular edema: visual disturbances requiring ophthalmic evaluation. - Progressive multifocal leukoencephalopathy: rare viral brain infection. - Severe liver injury: marked transaminase elevation or hepatitis. - Malignancy: increased risk of certain cancers.

Before initiating Mulfinya, several safety considerations should be observed.

- Pregnancy: contraindicated; avoid use during pregnancy. - Liver function: monitor transaminases before and during therapy. - Cardiac assessment: perform baseline ECG and monitor heart rate after first dose. - Ophthalmic monitoring: conduct regular eye exams to detect macular edema. - Live vaccines: avoid administration while on therapy. - Store at ambient temperature: keep in the original pack, protect from moisture.

Fingolimod interacts with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase fingolimod exposure. - Other S1P modulators: additive immunosuppression risk. - Live vaccines: heightened infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Beta‑blockers: may exacerbate bradycardia. - Antihypertensives: potential additive blood pressure effects. - Non‑live vaccines: monitor immune response.